Oncolytics Biotech Inc. Enters into At-the-Market Sales Agreement and Plans U.S. Domestication

On October 17, 2025, Oncolytics Biotech Inc. entered into an At-the-Market Sales Agreement with BTIG, LLC, allowing the company to offer and sell up to $50 million of its common shares. The shares will be sold from time to time based on the company's instructions, with BTIG acting as the sales agent. The company plans to use the net proceeds from the sales to fund the clinical development of pelareorep, associated research and development expenses, operating costs, and general corporate purposes. Additionally, Oncolytics Biotech Inc. announced its intention to change its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA, effective January 1, 2026. This move aims to reduce regulatory burdens and costs associated with being subject to both U.S. and Canadian laws, and to facilitate long-term shareholder value creation. The company believes that Nevada's corporate laws will provide a more predictable legal environment compared to Delaware.